Hemoglobin Level, Coagulopathy Profile and Electrolyte Balance

Learn more about:
Related Clinical Trial
Exploratory Study of the Relationships Between the Biomarkers of Inflammation, Lipidome and Insulin Resistance and Disorders of Glycemic Regulation in a Cohort of Insulin-resistant Subjects Due to Excess Weight or Dunnigan’s Lipodystrophy Natural History of Pregnancy and Pregnancy Outcomes in Metreleptin-Treated vs Untreated Subjects With Lipodystrophy Intraoperative Fluid Management of Liposuction , Cardiometry Versus Rohrich Formula The Visceral Adiposity Measurement and Observation Study Evaluating the Performance and Safety of the Medical Device Plenhyage® in the Treatment of Dermal Tissue Defects Evaluating the Performance and Safety of the Medical Device Auralya® in the Treatment of Facial Dermal Tissue Defects Evaluating the Performance and Safety of the Medical Device Janesse in the Treatment of Facial Dermal Tissue Defects Evaluating Performance and Safety of the Medical Device Jalucomplex in the Treatment of Facial and Neck Tissue Defects Changes in Weight, Body Composition and Cardiac Risk After Discontinuing Abacavir Treatment in HIV-infected Individuals Changes in Weight, Body Composition and Metabolic Parameters After Discontinuing Dolutegravir or Tenofovir Disproxil Effect of Berberine on Metabolic Syndrome, Efficacy and Safety in Combination With Antiretroviral Therapy in PLWH. Hemoglobin Level, Coagulopathy Profile and Electrolyte Balance Seronegatives and Metabolic Abnormalities Protocol 2 (SAMA002): Study to Compare the Effect of Kaletra and Combivir® in HIV-Negative Healthy Subjects Myocardial Function & FFA Metabolism in HIV Metabolic Syndrome Exercise and Pioglitazone for HIV-Metabolic Syndromes Observational Study of Changes in Fat Distribution and Blood Metabolites in HIV Infected Adults Yoga for the Management of HIV-Metabolic Syndromes Pravastatin for Hyperlipidaemia in HIV. A Study of Physical and Metabolic Abnormalities in HIV Infected and Uninfected Children and Youth Exercise for Patients With HIV Infections Lactate Metabolism Study in HIV Infected Persons Quality of Life, Sleep, and Biomarkers in People With HIV/AIDS The Effect of Efavirenz and Nelfinavir on the Blood Levels of Certain Lipid-Lowering Drugs Metformin and Rosiglitazone, Alone or in Combination, in HIV-Infected Patients With Insulin and Fat Abnormalities Effects of Treatment Changes on Fat Wasting in the Arms and Legs of HIV Patients Safety Study of Antria Cell Preparation Process to Enhance Facial Fat Grafting With Adipose Derived Stem Cells Growth Hormone Dynamics and Cardiac Steatosis in HIV The Effect of Anti-HIV Treatment on Body Characteristics of HIV-Infected Children Immune Response to Pneumococcal Vaccination in Aging HIV Positive Adults Switching From Zidovudine to an NNRTI or Lopinavir/Ritonavir in Patients Treated With Zidovudine/ Lamivudine/Abacavir. Phase 1 Study to Assess the Safety and Tolerability of TAT4 Gel in Healthy Volunteers Detraining in People Living With HIV/AIDS SHARE: Simple HAART With Abacavir, Reyataz, and Epivir The Effects of Anabolic Steroids and Protease Inhibitors on People Living With HIV/AIDS Observational Study of Fat Loss in HIV Infected Adults Taking Nucleoside Reverse Transcriptase Inhibitors (NRTIs) Metabolism and Body Shape of Healthy Children and Children With Chronic Infections Changing to Nonprotease Inhibitor Treatment to Improve Side Effects Safety and Effectiveness of Fenofibrate and Pravastatin in HIV-Positive Patients With Abnormal Blood Lipids Perceived Changes in Body Build and Image in Patients Who Are Now Taking or Recently Have Stopped Taking Anti-HIV Drugs White Light Scanning to Aid Body Contouring: A Pilot Project Treatment of Abnormal Adipose Tissue Accumulation in Human Immunodeficiency Virus (HIV) Patients The Effect of Low-Dose Human Growth Hormone Therapy in HIV Infected Patients Study Comparing Reducing the Dose of Stavudine Versus Switching to Tenofovir in HIV-Infected Patients Receiving Antiretroviral Therapy The Cleveland Cardiometabolic Cohort Metabolic Abnormalities in HIV-infected Persons Clinical Evaluation of Venus Versa Octipolar Applicator for Reduction of Abdomen Circumference Factors Mediating Gut Microbiota Dysbiosis and Metabolic Disease in HIV Patients. Underlying Abnormalities in Fat and Muscle Leading to Lipodystrophy Syndrome Effects of Short-term Growth Hormone in HIV-infected Patients Safety Study of Filler Agent Composed of Autologous Mesenchymal Stem Cells and Hyaluronic Acid Raltegravir Therapy for Women With HIV and Fat Accumulation The PREFORM Study: A Study to Evaluate the Safety and Efficacy of Rotational Fractional Resection on Submental Contouring Effects of IGF-I in HIV Metabolic Disease Combination of Insulin Sensitizer and Leptin as Treatment for the HAART -Induced Metabolic Syndrome Effectiveness of Nucleoside Supplementation or Switch to Tenofovir in Reversing Fat Loss in HIV Infected Adults Lopinavir/r Monotherapy Versus Abacavir/Lamivudine and Lopinavir/r for Limb Fat Recovery in Persons With Lipoatrophy Effects of Growth Hormone Releasing Hormone in HIV A Study of Increased Lactic Acid and Abnormal Fat Distribution in HIV-Positive Patients Effects of a Uridine Supplement on HIV Infected Adults With Lipoatrophy Body Composition and Adipose Tissue in HIV Study to Evaluate Changes in Limb Fat When Switching From a Thymidine Analogue CONFORM: Rotational Fractional Resection for Submental Contouring Study of Alpha-2 Adrenergic Receptor Dysfunction in Regional Lipoatrophy TH9507 in Patients With HIV-Associated Lipodystrophy TH9507 Extension Study in Patients With HIV- Associated Lipodystrophy Study Evaluating the Impact on Fat Distribution of Nucleoside Reverse Transcriptase Inhibitor (NRTI)-Sparing Regimens in Antiretroviral Experienced Patients With Lipoatrophy Energy Expenditure of People Living With HIV/AIDS Beneficial Effect of Insulin Glulisine by Lipoatrophy and Type 1 Diabetes (LAS) Egrifta Replacement and Sleep Disordered Breathing Clinical Trial to Determine the Efficacy of Sculptra™ Dermal Filler for the Correction of Contour Deformities Caused by Lipoatrophy Clinical Trial to Assess the Effect of the Change of Efavirenz (EFV) for Lopinavir/Ritonavir (LPV/r) in Lipoatrophy in HIV-infected Patients Low Energy Diet and Familial Partial Lipodystrophy Clinical Protocol to Investigate the Efficacy of Recombinant Human Leptin (Metreleptin) in Nonalcoholic Steatohepatitis (NASH) or Nonalcoholic Fatty Liver Disease (NAFLD) Associated With Lipodystrophy A Study to Determine How and Why HIV-Infected Subjects on Anti-viral Treatment Develop Lipodystrophy Adipocyte, Insulin-resistance and Immunity : Evaluation of Interleukin-7 in Lipodystrophy, Diabetes and Obesity Compassionate Use of Metreleptin in Previously Treated People With Generalized Lipodystrophy Role of the Autonomic Nervous System in HIV-Lipodystrophy Leptin for Abnormal Lipid Kinetics in HIV Lipodystrophy Syndrome Therapeutic Approaches to HAART-Induced Lipodystrophy Different Surgical Modalities for Thigh Lipodystrophy Including Liposuction,Thigh Lift and Liposuction Assisted Thigh Lift Leptin to Treat Lipodystrophy Compassionate Use of Metreleptin in Previously Treated People With Partial Lipodystrophy Prevalence of Lipodystrophy Syndrome and Its Role as Cause of Metabolic Disturbances Efficacy, Safety and Tolerability of ISIS 304801 in People With Partial Lipodystrophy With an Open-Label Extension Shock Waves for Treatment of Gynoid Lipodystrophy and Localized Fat Corticosteroid-induced Lipodystrophy and Adipokines Short-term Effects of Leptin in People With Lipodystrophy Leptin to Treat Lipodystrophy Lipodystrophy Connect Patient Registry An Open-Label Treatment Protocol to Provide Metreleptin for the Treatment of Diabetes Mellitus and/or Hypertriglyceridemia Associated With Lipodystrophy Autologous Adipose-Derived Stem Cell Transplantation in Patients With Lipodystrophy

Brief Title

Hemoglobin Level, Coagulopathy Profile and Electrolyte Balance

Official Title

Comparing the Changes in Hemoglobin Level, Coagulopathy Profile and Electrolyte Balance in Large Volume Liposuction Patients But in Different Surface Areas.

Brief Summary

      What is Impact of Amount Versus Surface Area of Liposuction on Haematological Parameters,
      Coagulopathy Profile and Electrolyte Balance? Liposuction involves the creation of extensive
      subsurface trauma, comparable in many respects to the massive injury of an internal burn.
      Liposuction commences with cannula aspiration of several liters of fluid-engorged adipose
      tissue, during which small feeder vessels are inevitably torn.

      Operating on multiple areas increases the area of injury regardless of whether just small
      amounts of fat are removed. Because many of the complications associated with large volume
      liposuction are related to fluid shifts and fluid balance, classifying the procedure based on
      the total volume removed from the patient, including fat, wetting solution, and blood, makes
      more sense to evaluate the damage made by the procedure.

      Safety and aesthetic issues define large-volume liposuction as having a 5,000-ml aspirate,
      mega-volume liposuction as having an 8,000-ml aspirate, and giganto-volume liposuction as
      having an aspirate of 12,000 ml or more.

Detailed Description

      Liposuction is fat- removing aesthetic surgery procedure that aims to body contouring.
      Liposuction is the most frequently performed aesthetic surgery procedure in Western
      Countries. This technique has had rapid development since the 1970s, when it was experimented
      for the first time by A. and G. Fischer. It is currently widely used in clinical practice for
      many different situations in aesthetic, reconstructive and functional fields.

      At 1970s, fat removal was carried out with a blunt curette. This technique was modified in
      1977 by a French surgeon, Yves Gerard Illouz, who added hyaluronidase and saline to emulsify
      the fatty tissue, and hence facilitate aspiration with the use of liposuction cannula. This
      was termed the 'wet technique' and was introduced to reduce blood loss during the procedure.

      The current options for wetting solutions are dry, wet, superwet, and tumescent. The dry
      technique employs no wetting solution and has few indications in liposuction. The wet
      technique involves instillation of 200 to 300 mL of solution per area to be treated,
      regardless of the amount aspirated. The superwet technique employs an infiltration of 1 mL
      per estimated mL of expected aspirate, and this is the technique practiced at our
      institution. Tumescent infiltration, popularized by Klein, involves infiltration of wetting
      solution that creates significant tissue turgor and results in infiltration of 3 to 4 mL of
      wetting solution per mL aspirated. Regardless of technique, the infiltrate should be allowed
      to take effect for seven minutes prior to suctioning.

      Most studies consider the most important parameter, to determine the safety of liposuction,
      is the amount (volume) of aspirated fluid. A review of the scientific literature shows that
      there are no scientific data available to support a specific volume maximum at which point
      liposuction is no longer safe, although the risk of complications is unavoidably higher as
      the volume of aspirate and the number of anatomic sites treated increase.

      Safety and aesthetic issues define large-volume liposuction as having a 5,000-ml aspirate,
      mega-volume liposuction as having an 8,000-ml aspirate, and giganto-volume liposuction as
      having an aspirate of 12,000 ml or more.

      In large volume liposuction, there is potential for large fluid shifts secondary to the
      volume of tissue removed, with a risk of developing pulmonary edema, high-volume liposuction
      is significantly more prone to complications than the original form of liposuction.

      There is a long history of debate over the safe volume of fat tissue that can be removed by
      liposuction. Current ASPS guidelines define 5,000 milliliters (five liters) as "large-volume
      liposuction" potentially associated with a higher risk of complications. But the guidelines
      acknowledge there is no scientific data to support an absolute cutoff point. Patients with
      complications had larger liposuction volumes-average 3.4 liters-and higher BMIs. Patients
      undergoing "large-volume" liposuction of more than five liters had a higher overall
      complication rate: 3.7 versus 1.1 percent.

      On the other hand, liposuction involves the creation of extensive subsurface trauma,
      comparable in many respects to the massive injury of an internal burn. Liposuction commences
      with cannula aspiration of several liters of fluid-engorged adipose tissue, during which
      small feeder vessels are inevitably torn.

      Only few studies have mentioned the effect of surface area on liposuction and none of those
      studies have been published at certified impacted magazine.

      In this study considers the amount of liposuction is a constant factor (Large volume
      liposuction) and the surface area is the variant to detect the changes in hemogram,
      coagulation profile and electrolyte imbalance that may lead to possible complication.

Study Type

Observational [Patient Registry]

Primary Outcome

Comparing the blood hemoglobin level pre, intra and post operative between two groups of patients, both have done large volume liposuction, with different surface areas liposuctioned.






* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information

Recruitment Status


Estimated Enrollment


Start Date

November 1, 2020

Completion Date

October 31, 2022

Primary Completion Date

June 30, 2022

Eligibility Criteria

        Inclusion Criteria:

          1. Female patient.

          2. Age: 25-45 years.

          3. BMI <40

          4. Large volume liposuction

          5. Patient asking for liposuction or suction assisted lipoectomy.

        Exclusion Criteria:

          1. Male patient.

          2. Age >45 or <25 years.

          3. Uncontrolled chronic diseases as DM, HTN.

          4. Show degrees of lipodystropy at breast.




25 Years - 45 Years

Accepts Healthy Volunteers

Accepts Healthy Volunteers


Assem H. Abdelhafez, professor, 01096778330, [email protected]

Location Countries


Location Countries


Administrative Informations



Organization ID

large volume liposuction

Responsible Party


Study Sponsor

Alaa Hassan M. Elhawary

Study Sponsor

Assem H. Abdelhafez, professor, Study Chair, Assiut University

Verification Date

November 2020